文献速递流行病学与生物统计真实世界研究与卫生经济

妊娠、易栓症与首次静脉血栓风险:系统综述与贝叶斯荟萃分析

Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis.
PubMed 文献 · BMJ · 2017-10-26

该系统综述与贝叶斯荟萃分析纳入36项未使用抗凝剂的妊娠观察性研究,评估遗传性易栓症与妊娠相关首次静脉血栓栓塞症(VTE)风险的关联。所有易栓症均升高妊娠相关VTE风险(概率≥91%);抗凝血酶、蛋白C、蛋白S缺乏及纯合因子V Leiden的绝对风险较高,而杂合因子V Leiden、杂合凝血酶原G20210A及复合杂合者的产前产后合并绝对风险均低于3%。

要点

  • 抗凝血酶缺乏者产前VTE绝对风险7.3%、产后11.1%,为高危易栓症。
  • 蛋白C缺乏产前3.2%、产后5.4%;蛋白S缺乏产前0.9%、产后4.2%。
  • 杂合因子V Leiden、杂合凝血酶原G20210A及复合杂合者合并绝对风险均低于3%。

核心结论

  • 抗凝血酶、蛋白C或蛋白S缺乏及纯合因子V Leiden的孕妇应考虑产前和/或产后血栓预防。
  • 杂合因子V Leiden、杂合凝血酶原G20210A或复合杂合者一般不应仅基于易栓症和家族史给予血栓预防。
  • 这些数据应纳入未来妊娠相关VTE风险指南的考虑。

研究设计与样本

  • 系统综述与贝叶斯荟萃分析,检索Embase、Medline、Web of Science、Cochrane Library和Google Scholar自建库至2016年11月14日。
  • 纳入报告未使用抗凝剂的妊娠及易栓症妇女首次VTE结局的观察性研究,共纳入36项研究。

主要发现

  • 所有易栓症均升高妊娠相关VTE风险(概率≥91%)。
  • 抗凝血酶缺乏产前绝对风险7.3%(95%可信区间1.8%至15.6%),产后11.1%(3.7%至21.0%)。
  • 蛋白C缺乏产前3.2%(0.6%至8.2%),产后5.4%(0.9%至13.8%)。
  • 蛋白S缺乏产前0.9%(0.0%至3.7%),产后4.2%(0.7%至9.4%)。
  • 纯合因子V Leiden产前2.8%(0.0%至8.6%),产后2.8%(0.0%至8.8%)。

关键数值与推荐

  • 杂合因子V Leiden、杂合凝血酶原G20210A突变或复合杂合因子V Leiden与凝血酶原G20210A突变者,产前产后合并绝对风险均低于3%。

临床怎么用

  • 作者认为,抗凝血酶、蛋白C或蛋白S缺乏或纯合因子V Leiden的妇女应考虑产前或产后血栓预防,或两者兼有。
  • 作者认为,杂合因子V Leiden、杂合凝血酶原G20210A突变或复合杂合者一般不应仅基于易栓症和家族史给予血栓预防。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective To provide evidence to support updated guidelines for the management of pregnant women with hereditary thrombophilia in order to reduce the risk of a first venous thromboembolism (VTE) in pregnancy.Design Systematic review and bayesian meta-analysis.Data sources Embase, Medline, Web of Science, Cochrane Library, and Google Scholar from inception through 14 November 2016.Review methods Observational studies that reported on pregnancies without the use of anticoagulants and the outcome of first VTE for women with thrombophilia were eligible for inclusion. VTE was considered established if it was confirmed by objective means, or when the patient had received a full course of a full dose anticoagulant treatment without objective testing. Results 36 studies were included in the meta-analysis. All thrombophilias increased the risk for pregnancy associated VTE (probabilities ≥91%). Regarding absolute risks of pregnancy associated VTE, high risk thrombophilias were antithrombin deficiency (antepartum: 7.3%, 95% credible interval 1.8% to 15.6%; post partum: 11.1%, 3.7% to 21.0%), protein C deficiency (antepartum: 3.2%, 0.6% to 8.2%; post partum: 5.4%, 0.9% to 13.8%), protein S deficiency (antepartum: 0.9%, 0.0% to 3.7%; post partum: 4.2%; 0.7% to 9.4%), and homozygous factor V Leiden (antepartum: 2.8%, 0.0% to 8.6%; post partum: 2.8%, 0.0% to 8.8%). Absolute combined antepartum and postpartum risks for women with heterozygous factor V Leiden, heterozygous prothrombin G20210A mutations, or compound heterozygous factor V Leiden and prothrombin G20210A mutations were all below 3%. Conclusions Women with antithrombin, protein C, or protein S deficiency or with homozygous factor V Leiden should be considered for antepartum or postpartum thrombosis prophylaxis, or both. Women with heterozygous factor V Leiden, heterozygous prothrombin G20210A mutation, or compound heterozygous factor V Leiden and prothrombin G20210A mutation should generally not be prescribed thrombosis prophylaxis on the basis of thrombophilia and family history alone. These data should be considered in future guidelines on pregnancy associated VTE risk.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Croles FN, Nasserinejad K, Duvekot JJ, et al. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ. 2017. PMID: 29074563. doi:10.1136/bmj.j4452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。